r.villalobos
TL2 Moderator · Izmir
Contributes reviews on supplier material. Based in Izmir.
Joined 18 October 2024 · last posted 2h
83Posts here
0Topics
1Solutions
484Likes received
397Likes given
19Badges
143Days visited
1.7kPosts read
Recent activity
Full stream-
Reference intervals: how they are constructed and why one in twenty flags — does this… Replied, post #23 · Clinical › Bloodwork · 28 Jul 2026 · 0 likes Time of day: some biomarkers vary across the day. Cortisol in the morning differs from cortisol in the evening. Comparing results from different times of day is…
-
[2026 update] Antibiotics and a course of something with delayed emptying Replied, post #73 · Practice › Interactions · 22 Jul 2026 · 23 likes Practical note that does not fit anywhere else. Whatever you conclude from this topic, write down what you did and when. The single most useful thing in your own…
-
[2026 update] Interpreting a result that disagrees with the supplier's certificate Replied, post #111 · Sourcing › Independent verification · 21 Jul 2026 · 1 like When results are inconclusive: if a testing service reports "insufficient to verify" on a documentation review, that is not a negative finding about the product. It…
-
Journal club: SUSTAIN 6 and its retinopathy signal Replied, post #66 · Evidence › Journal club · 15 Jul 2026 · 0 likes STEP 1 (N Engl J Med 2021): The pivotal obesity trial for semaglutide and the reference point for most subsequent comparison. Mean weight reduction was substantially…
-
Coming back to: A community side-effect dataset, with its response rate and biases Replied, post #91 · Data & Tools › Datasets · 5 Jul 2026 · 20 likes Community-collected datasets: some members have compiled datasets from their own experience and shared them. They are self-reported, unblinded, and therefore limited as…
-
Coming back to: When a red flag was a misunderstanding, and the retraction Replied, post #9 · Sourcing › Red flags · 5 Jul 2026 · 4 likes Anonymity: a supplier that will not disclose legal name, address, or responsible person is not operating in a way that allows accountability.
-
Journal club: indirect comparison between two programmes, defended and attacked Replied, post #106 · Evidence › Journal club · 4 Jul 2026 · 20 likes FLOW (N Engl J Med 2024): Semaglutide renal outcomes in type 2 diabetes and chronic kidney disease. Stopped early for efficacy. Component-by-component analysis is…
-
Research-use-only status: what it means legally and practically Replied, post #68 · Compounds › Other compounds · 2 Jul 2026 · 18 likes This subcategory exists because some people will research compounds outside the main groups discussed here. The standard of evidence and honesty about its limits…
-
Tesamorelin has an approved indication — what that changes about the evidence Replied, post #20 · Compounds › Secretagogues & GH axis · 1 Jul 2026 · 2 likes Secretagogues and glucose tolerance: there is a mechanistic concern that sustained growth hormone elevation might impair glucose tolerance. The clinical relevance of…
-
About the Mass spectrometry category Replied, post #5 · Analytics › Mass spectrometry · 27 Jun 2026 · 3 likes Common adducts: sodium adds ≈22, potassium adds ≈38 compared to hydrogen. A [M+Na]+ peak is common and its mass is predictable from the base mass.
-
Why a glucagon receptor agonist in a weight-loss compound is not a contradiction Replied, post #15 · Compounds › Retatrutide · 26 Jun 2026 · 4 likes Triple agonism: is the effect additive, synergistic, or neither? A phase 2 comparison of tirzepatide (dual) to retatrutide (triple) would answer that question. The…
-
A pooled estimate that changed when one trial was added Replied, post #12 · Evidence › Meta-analyses · 20 Jun 2026 · 28 likes I read post #10 twice before replying, because I had assumed the opposite. Study quality and weighting: some meta-analyses weight all studies equally; others weight by…